Preliminary Results of a Phase 1 Study of Flotetuzumab, a CD123 x CD3 Bispecific Dart® Protein, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic SyndromeGeoffrey L. Uy, John F. DiPersio, Matthew C. Foster et al.|Blood|2017Cited by 62
A phase I, first-in-human study of MGD006/S80880 (CD123 x CD3 DART) in AML/MDS.Norbert Vey, John F. DiPersio, Jan Davidson‐Moncada et al.|Journal of Clinical Oncology|2017Cited by 8